The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.
Also called NCT04572724
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 120 participants
- Registry
-
NCT04572724
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT04572724. Non-randomized; no masking; primary purpose treatment. Start 2020-07-06 (actual); primary completion 2022-11 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value
- Condition
- Peritoneal Dialysis Complication
- Condition
- Hemodialysis Complication
- Condition
- Heart Failure
- Intervention (Drug)
- Sacubitril / Valsartan Oral Tablet
- Intervention (Drug)
- RAS Inhibitors
- Lead sponsor
- Shenzhen Second People's Hospital
Record details
- Record id
cardio:ct-nct04572724- Content hash
fd96848f88cee677f99daeeab8585a9968b249c3eabafd214830eea91ba390cd